Drug intelligence / Profile preview

NBL-023

Development stage: Preclinical
Lead developer: Bionyra Pharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Parenteral

Overview

NBL-023 is a monoclonal antibody targeting interleukin-25 (IL-25), currently under development by NovaRock Biotherapeutics. IL-25 is a member of the IL-17 cytokine family that acts as a potent initiator of Type 2 inflammation by activating group 2 innate lymphoid cells (ILC2s) and Th2 cells. By blocking IL-25 signaling, NBL-023 is designed to suppress the production of downstream cytokines like IL-4, IL-5, and IL-13, which are central to the pathogenesis of allergic and inflammatory diseases. The drug is being investigated for the treatment of asthma, atopic dermatitis, chronic obstructive pulmonary disease (COPD), and ulcerative colitis, and is currently in the IND-enabling phase.

Targets

IL25 (IL-25)FCGRT (Neonatal crystallizable fragment receptor)

Beyond the preview

Go deeper on NBL-023.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NBL-023.

Explore the full profile